Results 71 to 80 of about 447,577 (315)

EGFR-targeted therapy

Experimental Cell Research, 2011
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L, Jacobs B, Normanno N, CIARDIELLO, Fortunato, Tejpar S.   +4 more
openaire   +4 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

Сибирский онкологический журнал, 2018
Activating mutations of EGFR are associated with sensitivity of non-small cell lung cancer (NSCLC ) to tyrosine kinase inhibitors (TKI). Liquid biopsy using circulating cell-free tumor DNA (cfDNA) is proposed in cases when formalin fixed paraffin ...
V. A. Shamanin, I. V. Karpov, P. А. Gervas, N. V. Cherdyntseva, E. I. Simolina, V. V. Kozlov, S. P. Kovalenko   +6 more
doaj   +1 more source

The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast

Türk Patoloji Dergisi, 2020
Objective: Basal markers [cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)] are used in identifying the basal-like breast carcinoma subtype, which is associated with a poor prognosis.
Fikret DIRILENOĞLU, Demet ARIKAN ETIT, Halil TAŞKAYNATAN, Ferhan ELMALI   +3 more
doaj   +1 more source

EGFR Mutation Status and PD-L1 Expression in Patients ≤40 Years Old with NSCLC

Zhongliu Fangzhi Yanjiu, 2022
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics.
HU Mingming, LIU Zichen, ZHANG Hongmei, LU Baohua, LI Jie, WANG Qunhui, HU Fanbin, LIN Haifeng, LI Baolan, ZHANG Tongmei   +9 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner

Cancer Management and Research, 2020
Yuntao Shi,1,* Yingying Zhuang,2,* Jialing Zhang,1 Mengxue Chen,1 Shangnong Wu1 1Department of Gastroenterology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China ...
Shi Y, Zhuang Y, Zhang J, Chen M, Wu S
doaj  

CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

Cells, 2020
CDK7, a transcriptional cyclin-dependent kinase, is emerging as a novel cancer target. Triple-negative breast cancers (TNBC) but not estrogen receptor-positive (ER+) breast cancers have been reported to be uniquely sensitive to the CDK7 inhibitor THZ1 ...
Martina S.J. McDermott, Amanda C. Sharko, Jessica Munie, Susannah Kassler, Theresa Melendez, Chang-uk Lim, Eugenia V. Broude   +6 more
doaj   +1 more source

Going beyond EGFR

Annals of Oncology, 2012
a substantial proportion of non-small-cell lung cancer (NSCLC), and adenocarcinoma in particular, depends on a so-called 'driver mutation' for their malignant phenotype. This genetic alteration induces and sustains tumorigenesis, and targeting of its protein product can result in growth inhibition, tumor response and increased patient survival.
Zimmermann, S., Peters, S.
openaire   +4 more sources

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

, 2011
Background:The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer.
F Solca, Solca, F, D Mackintosh, Guertler, U, Modjtahedi, H, Mackintosh, D, A G Dalgleish, Seddon, AM, Dalgleish, AG, N Ioannou, A M Seddon, U Guertler, Ioannou, N, Dalgleish, A G, H Modjtahedi, Seddon, A M   +15 more
core   +1 more source